Chairman Jeong-Sun Seo


  • 1980Ph.D. in Biochemistry and Molecular Biology,
    Seoul National University College of Medicine, Republic of Korea
  • 1976M.D., Seoul National University College of Medicine, Republic of Korea


  • 1997-PresentChairman & Founder, Macrogen Inc.,
    Republic of Korea
  • 2018-PresentDirector, Precision Medicine Center, Seoul National University Bundang Hospital,
    Republic of Korea
  • 2017-PresentDistinguished Professor, Seoul National University Bundang Hospital, Republic of Korea
  • 2017-PresentChairman, Gong-Wu Genome Information Foundation (G2IF), Republic of Korea
  • 2009-PresentPresident, Korea Biotechnology Industry Organization, Republic of Korea
  • 2005-PresentChairman, Biomedical hub advisory committee of IFEZ, Republic of Korea
  • 2004-Present Chairman of the Board, Macrogen Inc., Republic of Korea
  • 1997-2017 Director, ILCHUN Genomic Medicine Institute (GMI), SNU MRC, Republic of Korea
  • 1983-2017 Professor, Seoul National University,
    Republic of Korea
  • 2009President, Korean Society for Biochemistry and Molecular Biology (KSBMB), Republic of Korea
  • 2008 President, The Korean Society of Medical Biochemistry and Molecular Biology, Republic of Korea
  • 2007-2009President, Korea Bio Venture Association, Republic of Korea
  • 2005 President, Korea Genome Organization (KOGO), Republic of Korea
  • 2001-2002Scientific Advisor, Ministry of Health & Welfare, Republic of Korea
  • 2000-2004 CEO, Macrogen Inc., Republic of Korea
  • 2012-PresentEditor, PLOS One Journal, USA
  • 2005-PresentFull Member, American Society for Biochemistry and Molecular Biology (ASBMB), USA
  • 2003-PresentFull Member, The Korean Academy of Science and Technology (KAST), Republic of Korea
  • 1997-Present Editor, EMM Journal, Republic of Korea
  • 1997-Present Charter Member, International Molecular Biology Network (IMBN), Republic of Korea
  • 1987-Present Full Member, New York Academy of Science, USA

Message from the Chairman

Since the completion of the human genome map, a life-changing advancement achieved through the Human Genome Project,

the paradigm of healthcare has quickly shifted from treatment to illness prevention and health management. Furthermore, with the realization of the $1,000 genome, humankind is making great strides into the age of precision medicine – an age where big data integrating genomic data with medical data is used to predict, diagnose, and treat illnesses. From early on, Macrogen has recognized this paradigm shift in healthcare and the importance of genomics medicine, the core element of precision medicine. As a result, Macrogen has attained numerous outstanding R&D achievements in the field of human genomic analysis. In 2009, Macrogen successfully completed the whole-genome sequencing of a Korean individual. This was the fourth example of individual genome sequencing in the world, and the first case of Northern Asian genome sequencing. In 2016, Macrogen established the world’s most complete Asian reference genome, overcoming the limitations of the existing standard international reference genome and providing a new basis for future precision medicine.

Since 2009, Macrogen has been engaged in the ‘10,000 Asian Genome Project’, which focuses on genome sequencing for Northern Asians. Macrogen also recently assumed a leading role in the ‘Genome Asia 100K Initiative’, a project that involves the genome sequencing of 100,000 Asians across 19 countries in Asia. These and other projects play a critical role in cementing Macrogen’s precision medicine partnership network.

We at Macrogen pledge to continue to uphold our management philosophy of “Helping all of humankind to realize the dream of living a long healthy life through the utilization of genomic data.” It is our hope that, through our tireless R&D and international efforts, we can lead the realization of precision medicine for the 4.5 billion Asians worldwide. Thank you.

Chairman Jeong-Sun Seo